First cellularized collagen membrane implant to regenerate heart tissue in patients with ischemic heart disease

Thursday January 2nd, 2020 | General

3P Biopharmaceuticals and Viscofan go ahead with this innovative project of regenerative medicine for cardiac use. 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, and Viscofan BioEngineering, the Business Unit within the Viscofan Group), go one step further in an innovative cell therapy product. […]

A new anti-tumour treatment is one step closer to the clinic thanks to a new collaboration between In3Bio and 3P Biopharmaceuticals

Thursday November 28th, 2019 | General

3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, the UK based Biotech company, to collaborate in the development of a novel anti-tumour treatment. 3P Biopharmaceuticals and In3Bio began their partnership in early 2019 with 3P Biopharmaceuticals being selected to […]

3P Biopharmaceuticals initiates partnership with American Biotech Zhittya for Parkinson’s disease treatment

Monday October 21st, 2019 | General

3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, and the American biotech company, Zhittya Genesis Medicine (Zhittya), have successfully accomplished a tech transfer. 3P and Zhittya began their relationship at the beginning of 2019 with 3P being selected as the CDMO to transfer […]

3P Biopharmaceuticals receives FDA approval

Wednesday September 18th, 2019 | General

The FDA classified 3P facilities as acceptable for the manufacture of the target molecule, and appropriate for its commercialization in the US market, once the product is authorized. 3P Biopharmaceuticals a leading Contract Development and Manufacturing Organisation (CDMO) specialized in process development and GMP manufacturing of biologics, receives FDA approval after completing the Pre-Approval Inspection […]

The manufacturing process for Strangvac, the new vaccine against equine strangles, is proceeding according to plan

Tuesday August 27th, 2019 | General

The biotechnology company Intervacc has together with 3P Biopharmaceuticals, the contracted manufacturer of Strangvac, finalized the production of the drug substances on a commercial scale in compliance with GMP (Good Manufacturing Practice). “We are very pleased to announce that we have now manufactured the drug substances for several million doses of Strangvac, the new vaccine […]